Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wai Chun Bio-Technology Ltd. ( (HK:0660) ) has issued an update.
Wai Chun Bio-Technology Limited has announced a further delay to the dispatch of a shareholder circular relating to a loan agreement and associated drawdowns, as well as issues of non-compliance with listing rules. The circular, originally expected by 27 January 2026, is now scheduled to be sent on or before 25 February 2026 due to the additional time required to prepare and finalise financial information, signalling a short-term administrative setback that may prolong information asymmetry for shareholders and delay full clarity on the loan arrangements and regulatory matters.
More about Wai Chun Bio-Technology Ltd.
Wai Chun Bio-Technology Limited is a Hong Kong-listed company (Stock Code: 660) incorporated in the Cayman Islands, operating in the biotechnology sector. It is led by Chairman and Chief Executive Officer Lam Ka Chun and overseen by a board comprising one executive director and three independent non-executive directors.
Average Trading Volume: 109,716
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.48M
For detailed information about 0660 stock, go to TipRanks’ Stock Analysis page.